Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms - Full Text View

Sponsored by:	Department of Defense
Information provided by:	Tripler Army Medical Center
ClinicalTrials.gov Identifier:	NCT00160472

Purpose

This study will evaluate the expression of arginine vasopressin (AVP) by peptide and mRNA quantitation and also measurement of its V1 receptor mRNA, in the arteries and veins of ovarian malignant (cancerous) or benign (non-cancerous) tissue. We will examine whether AVP protein and AVP and V1 receptor mRNA expression vary with respect to tumor histology, intratumoral vascularization and systemic blood pressure.

Condition	Intervention
Ovarian Neoplasms	Procedure: removal of ovarian vessels

MedlinePlus related topics: Cancer Ovarian Cancer

Drug Information available for: Argipressin Vasopressins

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Bio-availability Study
Official Title:	Evaluation of Vasopressin and Vasopressin Receptor Expression in the Arteries and Veins of Ovarian Neoplasms

Further study details as provided by Tripler Army Medical Center:

Primary Outcome Measures:

1) Compare the levels of AVP and the vasopressin V1 receptor expression in the arteries and veins of ovarian tissue found to be cancerous versus ovarian tissue found to be noncancerous
2) Correlate the expression of AVP and its V1 receptor to stage of ovarian neoplasms graded by histology assessment
3) Correlate the expression of AVP and its receptor to intratumoral vascularization through Doppler ultrasound and systemic blood pressure.

Estimated Enrollment:	110
Study Start Date:	March 2004
Estimated Study Completion Date:	December 2005

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

All patients who have had gynecologic tissue removed for benign (noncancerous) or malignant (cancerous) indications.

Exclusion Criteria:

Patients who have a malignancy that is not a primary gynecologic malignancy.
Age less than 18
Males

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00160472

Contacts

Contact: John h FARLEY, md

808-433-6845

john.farley@us.army.mil

Locations

United States, Hawaii
Tripler Army Medical Center	Recruiting
Honolulu, Hawaii, United States, 96859
Contact: John H farley, MD 808-433-6845 john.farley@us.army.mil
Principal Investigator: John H Farley, MD

Sponsors and Collaborators

Department of Defense

Investigators

Principal Investigator:

John H Farley, MD

Tripler Army Medical Center

More Information

Study ID Numbers:	TAMC 3H04
Study First Received:	September 8, 2005
Last Updated:	November 28, 2005
ClinicalTrials.gov Identifier:	NCT00160472
Health Authority:	United States: Federal Government

Keywords provided by Tripler Army Medical Center:

vasopressin, ovarian, neoplas

Study placed in the following topic categories:

Arginine Vasopressin
Genital Diseases, Female
Ovarian cancer
Ovarian Neoplasms
Gonadal Disorders
Vasopressins

Genital Neoplasms, Female
Endocrine System Diseases
Urogenital Neoplasms
Endocrinopathy
Ovarian Diseases
Endocrine Gland Neoplasms

Additional relevant MeSH terms:

Coagulants
Hematologic Agents
Physiological Effects of Drugs
Cardiovascular Agents
Hemostatics
Pharmacologic Actions
Adnexal Diseases

Neoplasms
Neoplasms by Site
Natriuretic Agents
Therapeutic Uses
Vasoconstrictor Agents
Antidiuretic Agents

ClinicalTrials.gov processed this record on January 16, 2009